ABO blood group system and bone marrow transplantation.
The role of the ABO blood group system in determining the outcome of bone marrow transplantation was investigated in 53 patients with aplastic anemia and acute leukemia grafted from HLA-identical siblings. There was no correlation between ABO compatibility and marrow engraftment, graft rejection, or graft-versus-host disease. In 5 recipients with antibodies prior to transplantation to antigens of the ABH system present on the cells of their donors, plasma exchange and antibody absorption in vivo were effective in permitting engraftment of ABO-incompatible bone marrow. These findings indicate that the ABO system is not a clinically significant barrier to successful bone marrow transplantation in otherwise histocompatible individuals.
D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000528:radiation effects; D006086:Graft vs Host Disease / Q000628:therapy; D006648:Histocompatibility; D006801:Humans; D007165:Immunosuppression Therapy; D007518:Isoantibodies / Q000032:analysis; D007938:Leukemia / Q000628:therapy; D008297:Male; D013866:Thioguanine / Q000627:therapeutic use; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000017:ABO Blood-Group System; D000961:Antilymphocyte Serum; D007518:Isoantibodies; D003561:Cytarabine; D003520:Cyclophosphamide; D013866:Thioguanine; D003630:Daunorubicin